Overview

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

Status:
Completed

Trial end date:
2018-12-12

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection and Child-Pugh-Turcotte (CPT) Class C cirrhosis.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Sofosbuvir
Sofosbuvir-velpatasvir drug combination
Velpatasvir